NASDAQ:CRSP - CRISPR Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $157.67
  • Forecasted Upside: 20.65 %
  • Number of Analysts: 20
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.48 (1.15%)

This chart shows the closing price for CRSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

Analyst Price Target is $157.67
▲ +20.65% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $157.67, with a high forecast of $210.00 and a low forecast of $110.00. The average price target represents a 20.65% upside from the last price of $130.68.

This chart shows the closing price for CRSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 20 contributing investment analysts is to buy stock in CRISPR Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeSell ➝ Neutral$55.00 ➝ $132.00Low
6/14/2021CitigroupUpgradeSell ➝ Neutral$55.00 ➝ $132.00Low
5/13/2021Evercore ISIUpgradeOutperformHigh
4/21/2021BarclaysBoost Price TargetOverweight$140.00 ➝ $160.00High
4/21/2021Jefferies Financial GroupUpgradeHold ➝ Buy$172.00Medium
3/4/2021JMP SecuritiesInitiated CoverageOutperform$160.00High
3/1/2021BarclaysBoost Price TargetOverweight$113.00 ➝ $140.00Low
2/28/2021BarclaysReiterated RatingBuyLow
2/17/2021The Goldman Sachs GroupLower Price TargetNeutral$193.00 ➝ $189.00Medium
2/17/2021OppenheimerBoost Price TargetOutperform$165.00 ➝ $187.00Low
2/17/2021Chardan CapitalBoost Price TargetBuy$166.00 ➝ $175.00Low
2/17/2021Needham & Company LLCReiterated RatingBuyLow
1/12/2021TruistBoost Price Target$170.00 ➝ $210.00Low
12/10/2020Chardan CapitalBoost Price TargetBuy$110.00 ➝ $166.00High
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
12/10/2020Needham & Company LLCBoost Price TargetBuy$105.00 ➝ $170.00Medium
12/10/2020Piper SandlerBoost Price TargetOverweight$107.00 ➝ $180.00Medium
12/7/2020Stifel NicolausBoost Price TargetHold ➝ Positive$91.00 ➝ $145.00High
12/7/2020Canaccord GenuityBoost Price TargetBuy$120.00 ➝ $151.00Low
12/7/2020OppenheimerBoost Price TargetOutperform$105.00 ➝ $155.00High
12/7/2020Roth CapitalBoost Price TargetBuy$115.00 ➝ $170.00High
12/7/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00Low
10/30/2020Raymond JamesReiterated RatingSellHigh
10/29/2020Piper SandlerLower Price TargetOverweight$128.00 ➝ $107.00Medium
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$110.00 ➝ $110.00Medium
10/22/2020Canaccord GenuityBoost Price Target$110.00 ➝ $120.00High
10/22/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$100.00 ➝ $110.00High
10/21/2020Stifel NicolausBoost Price TargetHold$75.00 ➝ $93.00Medium
10/21/2020Roth CapitalBoost Price TargetBuy$105.00 ➝ $115.00High
10/21/2020Piper SandlerBoost Price TargetOverweight$104.00 ➝ $128.00High
10/5/2020Bank of AmericaInitiated CoverageBuy$110.00 ➝ $110.00High
8/5/2020CitigroupReiterated RatingSellLow
7/28/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $110.00High
7/28/2020Chardan CapitalBoost Price TargetBuy$72.50 ➝ $100.00High
7/28/2020Needham & Company LLCBoost Price TargetBuy$84.00 ➝ $105.00Medium
7/28/2020William BlairReiterated RatingBuyMedium
7/28/2020BarclaysBoost Price TargetPositive ➝ Overweight$65.00 ➝ $102.00High
7/27/2020OppenheimerInitiated CoverageBuy$89.00 ➝ $105.00Medium
7/14/2020SunTrust BanksInitiated CoverageBuy$140.00Low
6/23/2020OppenheimerBoost Price TargetOutperform$80.00 ➝ $89.00High
6/19/2020Piper SandlerReiterated RatingOverweight$104.00High
6/19/2020Roth CapitalBoost Price TargetBuy$100.00 ➝ $105.00Medium
6/15/2020Canaccord GenuityBoost Price TargetBuy$80.00 ➝ $84.00High
6/12/2020Piper SandlerReiterated RatingBuy$104.00Medium
6/12/2020Chardan CapitalReiterated RatingBuy$72.50Medium
6/12/2020Needham & Company LLCInitiated CoverageBuy$84.00Medium
6/12/2020OppenheimerInitiated CoverageBuy$80.00Low
5/31/2020Chardan CapitalReiterated RatingBuyMedium
5/6/2020Chardan CapitalReiterated RatingBuyMedium
4/29/2020Needham & Company LLCInitiated CoverageBuy$84.00High
4/28/2020William BlairReiterated RatingBuyHigh
4/1/2020Piper SandlerReiterated RatingBuy$104.00Low
3/4/2020Stifel NicolausInitiated CoverageHold$52.00Low
3/4/2020CitigroupBoost Price TargetSell$28.00 ➝ $31.00Medium
2/13/2020Piper SandlerReiterated RatingBuy$104.00High
2/13/2020Chardan CapitalReiterated RatingBuy$72.50High
2/13/2020William BlairReiterated RatingBuyHigh
1/30/2020Chardan CapitalReiterated RatingBuyMedium
12/23/2019Needham & Company LLCReiterated RatingBuy$84.00High
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Low
12/6/2019Wells Fargo & CompanyReiterated RatingBuyLow
11/26/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Medium
11/25/2019OppenheimerBoost Price TargetOutperform$65.00 ➝ $80.00Low
11/20/2019Canaccord GenuityBoost Price TargetBuy ➝ Positive$72.00 ➝ $80.00High
11/19/2019Roth CapitalBoost Price Target$65.00 ➝ $100.00High
11/19/2019Piper Jaffray CompaniesBoost Price TargetBuy$100.00 ➝ $107.00High
11/19/2019Wells Fargo & CompanyReiterated RatingBuyHigh
11/19/2019William BlairUpgradeMarket Perform ➝ OutperformHigh
11/19/2019The Goldman Sachs GroupBoost Price TargetPositive ➝ Neutral$52.00 ➝ $75.00High
11/18/2019Chardan CapitalReiterated RatingBuy$72.50High
11/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$65.00High
10/21/2019Chardan CapitalSet Price TargetBuy$72.50Low
10/21/2019Piper Jaffray CompaniesReiterated RatingOverweightHigh
10/15/2019Chardan CapitalReiterated RatingBuy$72.50Low
8/1/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$64.00Low
7/31/2019Needham & Company LLCReiterated RatingBuy$62.00Low
7/30/2019Roth CapitalBoost Price Target$50.00 ➝ $65.00Medium
7/30/2019BarclaysBoost Price TargetOverweight$59.00 ➝ $62.00Medium
7/30/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$51.00 ➝ $59.00Medium
7/30/2019William BlairReiterated RatingHoldMedium
7/26/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$72.00High
6/10/2019Roth CapitalInitiated CoverageBuy$50.00Medium
6/7/2019Chardan CapitalSet Price TargetBuy$73.00High
5/1/2019Needham & Company LLCReiterated RatingBuy$62.00Medium
4/22/2019BTIG ResearchBoost Price TargetBuy$30.00 ➝ $33.00Medium
4/11/2019Evercore ISIInitiated CoverageOutperformLow
3/13/2019William BlairInitiated CoverageMarket PerformLow
2/7/2019BTIG ResearchInitiated CoverageBuy$43.00Medium
1/28/2019The Goldman Sachs GroupDowngradeBuy ➝ Neutral$78.00 ➝ $40.00Low
1/22/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $21.00High
12/31/2018SunTrust BanksReiterated RatingBuyMedium
12/9/2018Needham & Company LLCInitiated CoverageBuy$62.00 ➝ $38.72Low
11/30/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$62.00Medium
10/10/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$65.00High
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/20/2018Raymond JamesInitiated CoverageUnderperform ➝ UnderperformHigh
8/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
8/8/2018Chardan CapitalReiterated RatingBuy$72.50High
5/15/2018Chardan CapitalBoost Price TargetBuy$25.00 ➝ $72.50Medium
4/6/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$86.00High
3/9/2018SunTrust BanksReiterated RatingBuy$65.00High
3/9/2018Piper Jaffray CompaniesReiterated RatingOverweight$67.00 ➝ $53.70High
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$69.00High
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$29.00 ➝ $59.00Low
2/28/2018CitigroupBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $51.00Medium
1/23/2018SunTrust BanksUpgradeHold ➝ BuyHigh
1/10/2018Piper Jaffray CompaniesReiterated RatingBuy$39.00 ➝ $22.75Low
12/22/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightHigh
12/21/2017OppenheimerReiterated RatingHoldHigh
12/7/2017OppenheimerInitiated CoverageHoldLow
11/10/2017SunTrust BanksReiterated RatingHold$16.00N/A
9/8/2017BarclaysReiterated RatingBuy$29.00Low
8/14/2017Chardan CapitalReiterated RatingBuyMedium
7/18/2017OppenheimerMarket PerformN/A
7/13/2017SunTrust BanksInitiated CoverageHold ➝ Hold$16.00Low
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$23.50High
2/16/2017Piper Jaffray CompaniesSet Price TargetBuy$21.00N/A
11/15/2016CitigroupInitiated CoverageNeutral$19.00N/A
11/14/2016GuggenheimInitiated CoverageBuy$30.00N/A
11/14/2016Piper Jaffray CompaniesInitiated CoverageOverweight$21.00N/A
11/14/2016BarclaysInitiated CoverageOverweight$22.00N/A
(Data available from 6/24/2016 forward)
CRISPR Therapeutics logo
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. It also has a strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Read More

Today's Range

Now: $130.68
Low: $128.63
High: $132.90

50 Day Range

MA: $119.24
Low: $100.84
High: $135.72

52 Week Range

Now: $130.68
Low: $68.85
High: $220.20


960,733 shs

Average Volume

1,833,798 shs

Market Capitalization

$9.90 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Chardan Capital, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, Jefferies Financial Group Inc., JMP Securities, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., TheStreet, Truist, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CRSP.

What is the current price target for CRISPR Therapeutics?

18 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $157.67, suggesting a possible upside of 20.7%. Truist has the highest price target set, predicting CRSP will reach $210.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $110.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.

What is the current consensus analyst rating for CRISPR Therapeutics?

CRISPR Therapeutics currently has 1 sell rating, 5 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRSP will outperform the market and that investors should add to their positions of CRISPR Therapeutics.
View the latest ratings for CRSP.

What other companies compete with CRISPR Therapeutics?

How do I contact CRISPR Therapeutics' investor relations team?

CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is 41-41-561-3277 and its investor relations email address is [email protected] The official website for CRISPR Therapeutics is